Well – Might be at a minor crossroads here. Wife was doing 12 rnds of FolFox+Avastin+Oxi and seen decent results during the chemo regiment. Coming off a Chemo break of 2.5 months, yesterday’s CT scan showed progression of disease in Colon/Lungs. CEA up from 0.6 to 2.6. Essentially we are at the starting point of Dx in November 2016 in relationship to size of Tumors/Mets. All ground gained on shrinkage has been overturned. Good news is no New areas of disease development.
Uploaded results to NIH/NCI today (Dr Rosenburg’s Office) and they are going to see if there are enough lesions that they can resect to include her in Clinical Trial NCT01174121 : "A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab ". Adherent problem is Roswell Park Onc wants to giddy up on Capecitabine + Bevacizumab in Early August 2017. No OXI (neuropathy). One Problem is, NCI would like to start clinical study BEFORE next line of chemo treatment. So I believe we will hold off chemo until we hear from NCI. NIH/NCI surgeons promised a quick review of all data. If we are accepted for clinical trail, we are looking at months down the road (cell harvesting, ect ect. ).
Questions/concerns – Do we take the risk of the Clinical Trial now or go back to Chemo that we know knocks it down… BUT appears not to be the final solution? Has anybody had luck in this trial NCT01174121 they can speak of first hand ? (I will of course search this forum). Thank you all in advance. sdino